Theravac Clone - Full Version

We advance the frontiers of science every day,
utilizing therapeutic vaccines and oncolytic viruses to create more targeted, effective, and personalized treatments for patients.

By leveraging the latest breakthroughs in immunology, molecular biology, and genetic engineering, our goal is to stimulate the body’s natural immune defenses to detect and destroy cancer cells—bringing renewed hope through long-lasting and precise therapies that overcome the limitations of traditional cancer treatments.

TheravacBio's immunotherapies

Our immune intervention strategies fall into two categories:
First, for subhealthy populations, we employ iNKT cell technology, which combines features of both innate and adaptive immunity, to restore immune homeostasis. This approach helps control inflammation, combat infections, resist tumors, regulate metabolism, and promote overall health.

Second, for cancer patients, we utilize the tumor therapeutic vaccines to overcome the bottlenecks of tumor immunosuppressive microenvironments, tumor heterogeneity, and low immunogenicity. This strategy aims to awaken and enhance tumor-specific protective immune responses, thereby inhibiting tumor growth.

Our Breakthrough Innovations

Discover how TheravacBio is pioneering immune-based therapies through advanced technologies and personalized solutions.

Therapeutic Tumor Vaccines

The introduction of immune checkpoint inhibitors (ICIs) has confirmed T-cell-mediated tumor control, highlighting the clinical value of T-cell-based immunotherapy. Key studies demonstrate that edongenous T cells can recognize mutated cancer-specific epitopes presented by major histocompatibility complexes (MHC/HLA), which mediate effective anti-tumor responses. However, since tumor antigens derive from normal cells, they possess low immunogenicity due to the immune system's tolearance to "self".This presents a challenge in activating robust immune responses through traditional methods, thereby hindering the development of therapeutic tumor vaccines.
Based on our innovative CY^plus adjuvant technology, we developed a therapeutic lung cancer vaccine (VKD-LMN/CY) using a recombinant viral vector. This vaccine incorporates an advanced adjuvant system that effectively activates the immune response, addressing the challenges posed by the weak immunogenicity of tumor antigens and the tumor's immunosuppressive microenvironment. It demonstrated robust broad-spectrum anti-tumor activity through the co-expression of multiple tumor antigens, thereby targeting tumor heterogeneity effectively.

Reconstruction of Immune homeostasis

Type I invariant natural killer T (iNKT) cells possess characteristics of both innate immunity (NK cells) and adaptive immunity (T cells). Upon activation, iNKT cells can specifically eliminate tumor and infected cells, removing those that pose a risk to the body’s health. They secrete various cytokines to modulate immune responses, maintaining a balanced state—preventing weakened immunity that could lead to cancer or infections while avoiding excessive immune responses that may cause allergies or autoimmune diseases. iNKT cells play a crucial role in anti-tumor defense, infection control, and immune regulation, surpassing the capabilities of NK cells.

We aim to harness the immune system's full potential by combining next-gen immunomodulatory strategies with diverse biological targets to treat cancer, infectious, and other high-burden diseases.

Featuring publications from the Principal
Investigator (PIs) and Team

2025 .Communications Medicine 5, 127 (2025). -187(17):4586-4604- Rabies virus large protein-derived T-cell immunogen facilitates rapid viral clearance and enhances protection against lethal challenge in mice

August 22, 2024 . Cell. -187(17):4586-4604- High expression of oleoyl-ACP hydrolase underpins life-threatening respiratory viral diseases

Oct, 2024 .Cell Discovery. 10, 49 (2024)- 4. Efficacy and Safety of Novel Multifunctional M10 CAR-T Cells in HIV-1-Infected Patients: A Phase I, Multicenter, Single-Arm, Open-Label Study.

Jun 14, 2024 .J Vis Exp. - doi: 10.3791/66697- Generation and Functional Verification of Hypoxia-sensitive Chimeric Antigen Receptor-T Cells.

Jun, 2023 Cancer Research Communications, 2023 Jun 7;3(6):991-1003. doi: 10.1158/2767-9764. CRC-23-0137 5. Safety and clinical response to combined immunotherapy with autologous iNKT cells and PD-1+CD8+ T cells in patients failing first-line chemotherapy in stage IV pancreatic cancer.

One Mission.
Endless Innovation.
A New Era Against Cancer.
Powered by viral vector expertise,
driven to save lives.

contact us

Call us
03 8564 8561

Email us
contact@theravacbio.com.au

Address
Suite 178, 793 Burke Road,
Camberwell, Victoria 3124

© 2024 Theravacbio Clone. All rights reserved.

Advancing Immunology for Cutting-Edge Patient Solutions

We advance the frontiers of science every day, utilizing therapeutic vaccines and oncolytic viruses to create more targeted, effective, and personalized treatments for patients.